Klinische Studien zu MDS
| Phase III | ELEMENT-MDS (CA056-025) | NCT05949684 Eudra-CT: 2022-500430-29-00 |
|---|---|---|
| CA056-025: A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The “ELEMENT-MDS” Trial | ||
| Weitere Informationen: | www.bmsstudyconnect.com - Studienwebseite von Bristol-Myers Squibb | |
| Ihr Ansprechpartner: | Studienassistentin Miwa Langer | Email senden |
| Telefon: | 0211 81-17714 | |
| Phase II | CanFire | 020-002246-16 |
|---|---|---|
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients with IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or CMML | ||
| Weitere Informationen: | http://www.klinische-studien-krebs.de/klinische-studien/?caseID=654 | |
| Ihr Ansprechpartner: | Studienassistentin Thi Nguyen | Email senden |
| Telefon: | 0211 81-17714 | Studie in Vorbereitung |
| Phase II | KER050-MD-201 | NCT04419649 |
|---|---|---|
| A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) | ||
| Weitere Informationen: | www.klinische-studien-krebs.de/klinische-studien/?caseID=659 | |
| Ihr Ansprechpartner: | Studienassistentin Thi Nguyen | Email senden |
| Telefon: | 0211 81-17714 | Studie in Vorbereitung |
| MDS Phase II/III | Imetelstat | 2015‐002874‐19 |
|---|---|---|
| A Study to Evaluate Imetelstat(GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | ||
| Weitere Informationen: | www.klinische-studien-krebs.de/klinische-studien/?caseID=653 | |
| Ihr Ansprechpartner: | Studienassistentin Thi Nguyen | Email senden |
| Telefon: | 0211 81-17714 | |
| MDS Phase III Roxadustat in lower-risk MDS | FGCL-4592-082 | EudraCT: 2017-001773-17 |
|---|---|---|
| A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB) | ||
| Weitere Informationen: | www.klinische-studien-krebs.de/klinische-studien/?caseID=599 | |
| Ihr Ansprechpartner: | Studienassistenz Miwa Langer | Email senden |
| Telefon: | 0211 81-17714 | |
| Phase III | M15-954 Verona | EudraCT: 2020-000744-55 |
|---|---|---|
| A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) | ||
| Weitere Informationen: | www.klinische-studien-krebs.de/klinische-studien/?caseID=643 | |
| Ihr Ansprechpartner: | Studienassistenz Miwa Langer | Email senden |
| Telefon: | 0211 81-17714 | |
| Phase III b | LUSPLUS | EudraCT: 2020-004899-18 |
|---|---|---|
A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS) | ||
| Weitere Informationen: | www.klinische-studien-krebs.de/klinische-studien/?caseID=608 | |
| Ihr Ansprechpartner: | Studienassistenz Miwa Langer | Email senden |
| Telefon: | 0211 81-17714 | Studie in Vorbereitung |